Vinpocetine, tablets 5 mg 50 pcs

Improves brain metabolism by increasing glucose and oxygen uptake by brain tissue. Increases resistance of neurons to hypoxia; facilitates transport of oxygen and energy supply substrates to tissues (due to decreased affinity of red blood cells to it, increased glucose uptake and metabolism, switching it to a more energetically beneficial aerobic direction).

It selectively blocks Ca2+/dependent phosphodiesterase (PDE); increases brain levels of adenosine monophosphate (AMP) and cyclic guanosine monophosphate (cGMP). Increases ATP concentration and ATP/AMP ratio in brain tissues; enhances brain noradrenaline and serotonin metabolism; stimulates ascending branch of noradrenergic system, has antioxidant effect.

Indications

Neurology: symptomatic treatment of the consequences of ischemic stroke, vascular vertebrobasilar insufficiency, vascular dementia, cerebral atherosclerosis, post-traumatic, hypertensive encephalopathy.
Ophthalmology: chronic vascular diseases of the retina and choroid.
Otology: perceptual hearing loss, Meniere’s disease, tinnitus.

Pharmacological effect

Improves brain metabolism by increasing the consumption of glucose and oxygen by brain tissue. Increases the resistance of neurons to hypoxia; facilitating the transport of oxygen and energy supply substrates to tissues (due to a decrease in the affinity of red blood cells for it, increased absorption and metabolism of glucose, switching it to an energetically more favorable aerobic direction).

Selectively blocks Ca2+/dependent phosphodiesterase (PDE); increases levels of adenosine monophosphate (AMP) and cyclic guanosine monophosphate (cGMP) in the brain. Increases the concentration of ATP and the ATP/AMP ratio in brain tissue; enhances the exchange of norepinephrine and serotonin in the brain; stimulates the ascending branch of the noradrenergic system and has an antioxidant effect.

Special instructions

In the case of initial prolongation of the Q-T interval, as well as when used simultaneously with drugs that prolong the Q-T interval, periodic ECG monitoring is required during treatment with vinpocetine.

Active ingredient

Vinpocetine

Composition

1 tablet contains:
active substance:
vinpocetine – 0.005 g
excipients:
lactose (milk sugar) – 0.17500 g
colloidal silicon dioxide (aerosil) – 0.00125 g
potato starch – 0.06625 g
talc – 0.00125 g
magnesium stearate – 0.00125 g

Contraindications

Acute phase of hemorrhagic stroke, severe form of coronary heart disease, severe cardiac arrhythmias. Hypersensitivity to vinpocetine or other components of the drug. Lactose intolerance, lactase deficiency, glucose-galactose malabsorption, since the drug contains lactose.
Pregnancy, breastfeeding period.
Children under 18 years of age (due to lack of clinical trial data).

With caution
Coronary heart disease (severe), severe rhythm disturbances (parenteral administration). In case of hemorrhagic stroke, parenteral administration is possible only after the acute effects have subsided (usually after 5-7 days).

Side Effects

Data on side effects are presented by system-organ classes in accordance with the MedDRA classification and with the following frequency: uncommon (≥1/1000, <1/100); rare (≥1/10000, <1/1000); very rare (<1/10000).

Interaction

The hypotensive effect may be enhanced when used simultaneously with methyldopa (blood pressure control is required).
Despite the lack of data confirming the possibility of interaction, caution is recommended when used simultaneously with centrally acting drugs, antiarrhythmics and anticoagulants.

Overdose

Treatment: gastric lavage, taking activated carbon, symptomatic treatment.

Shelf life

3 years.

Manufacturer

Update of PFC JSC, Russia